Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
CLPBY COLOPLAST SPON ADS EACH REPR 0.1 OD SHS
12.020
+0.260+2.21%
YOY
Do not show
Hide blank lines
(FY)2022/09/30(Q4)2022/09/30(Q3)2022/06/30(Q2)2022/03/31
Total revenue
16.23% 22.58B 18.80% 6.06B 20.97% 5.85B 15.76% 5.5B
Operating revenue
16.23% 22.58B 18.80% 6.06B 20.97% 5.85B 15.76% 5.5B
Cost of revenue
15.33% 7.05B 19.63% 1.89B 20.07% 1.8B 14.58% 1.72B
Gross profit
16.65% 15.53B 18.43% 4.17B 21.38% 4.05B 16.30% 3.78B
Operating expense
23.87% 8.62B 25.92% 2.36B 31.21% 2.29B 25.15% 2.1B
Selling and administrative expenses
24.89% 7.8B 28.85% 2.15B 31.42% 2.08B 25.60% 1.88B
-Selling and marketing expense
23.92% 6.8B 28.75% 1.87B 29.87% 1.81B 22.26% 1.62B
-General and administrative expense
31.89% 1.01B 29.58% 276M 42.86% 270M 50.86% 264M
Research and development costs
14.70% 866M 4.83% 217M 20.00% 222M 25.42% 222M
Other operating expenses
-13.79% 25M -53.85% 6M 140.00% 12M -42.86% 4M
Operating profit
8.73% 6.91B 9.94% 1.81B 10.62% 1.76B 6.91% 1.69B
Net non-operating interest income expense
-397.78% -224M -700.00% -80M -359.26% -70M -118.37% -18M
Non-operating interest income
9.09% 12M 66.67% 5M 79.55% 79M -48.98% 50M
Non-operating interest expense
588.00% 172M 1,433.33% 92M 776.47% 149M -- 68M
Total other finance cost
106.45% 64M -200.00% -7M -- -- -- --
Other net income (expense)
Special income (charges)
-135.50% -471M -- -36M -- -20M -90.50% -381M
-Less:Restructuring and merger&acquisition
-- 171M -- 36M -- -- -- --
-Less:Other special charges
50.00% 300M -- 0 -- 20M 90.50% 381M
Income before tax
-1.70% 6.13B -1.95% 1.61B 3.21% 1.67B -12.75% 1.29B
Income tax
0.92% 1.42B 12.68% 382M 4.66% 382M -11.01% 307M
Net income
-2.47% 4.71B -5.75% 1.23B 2.79% 1.29B -13.27% 980M
Net income continuous Operations
-2.47% 4.71B -5.75% 1.23B 2.79% 1.29B -13.27% 980M
Minority interest income
Net income attributable to the parent company
-2.47% 4.71B -5.75% 1.23B 2.79% 1.29B -13.27% 980M
Preferred stock dividends
Other preferred stock dividends
0 0 0 0
Net income attributable to common stockholders
-2.47% 4.71B -5.75% 1.23B 2.79% 1.29B -13.27% 980M
Basic earnings per share
-2.34% 2.214 -5.55% 0.579 3.06% 0.607 -13.18% 0.461
Diluted earnings per share
-2.30% 2.211 -5.39% 0.579 3.06% 0.606 -13.21% 0.46
Dividend per share
3.97% 1.8865 0 -2.28% 0.489 0
Currency Unit
DKKDKKDKKDKK

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.
CEO: Mr. Kristian Villumsen
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist